Director/PDMR Shareholding

Oxford Pharmascience Group plc

 ("Oxford Pharmascience" or the "Company")

Director/PDMR Shareholding

Oxford Pharmascience today announces that it was notified on 25 March 2014, that Mr. David Norwood, Non-executive Chairman of the Company, bought 1,000,000 shares of 0.1 pence each in the Company (the "Ordinary Shares") at a price of 4.3 pence per Ordinary Share. Following this transaction, Mr. Norwood has a beneficial interest in 105,938,633 Ordinary Shares representing approximately 10.62 per cent. of the total voting rights in the Company.

For further information:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Executive +44 20 7554 5875

N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell/Jen Boorer +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers, but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. 

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.